clinical-trials-2017-scientifictracks-abstracts

2 / 46

Page 35
Notes:
conferenceseries.com
Volume 7, Issue 5 (Suppl) J Clin Trials, an open access journal
ISSN:2167-0870 Clinical Trials 2017
September 11-13, 2017
September 11-13, 2017 San Antonio, USA
4th International Conference on
Cl inical Tr ial s
Developing an Alzheimer’s clinical trial network with the Carolinas healthcare system, a large
fully integrated health care system
Oleg V Tcheremissine and James C Rachal
Carolinas HealthCare System, USA
Alzheimer’s disease (AD) is a progressive neurogenerative disorder with a wide range of symptoms affecting memory,
concentration, volition, and almost all aspects of human behavior. The prevalence of patients with AD is increasing due to
an aging population. There is real possibility that without medical breakthroughs, the current 5.3 million Americans diagnosed
will triple to 13.8 million by 2050. Delivery of compressive care is facing a crisis stemming from a combination of factors like
the growing demand for such care, insufficient number of those specialized in this therapeutic area, rising costs of care, the
complexity of the diseases and lack of effective treatment. Despite massive research efforts in recent decades, new treatments
for AD remain elusive. Since 1998, there have been more than 100 attempts to develop new pharmacological agents, and all
have failed. Patient population included in these clinical trials typically suffered from mild-moderate AD. Most of them were
initially diagnosed and treated by their primary care providers. Early identification of a cohort of those who will benefit from
clinical trial participation by is a strategic priority. CHS has made an investment in developing a comprehensive dementia care
though a collaboration of different service lines including Neurosciences, Behavioral Health, Primary Care and Geriatrics.
This bidirectional reciprocity allows aligning the process of drug development with information derived at the point of care,
and provides an opportunity to further breech the efficacy-effectiveness gap, commonly defined as the differences between two
populations of patients, those enrolled in clinical trials and those who will be treated in real clinical settings.
Biography
Oleg V Tcheremissine, MD, is a Professor of Psychiatry and Research Director for the Carolinas HealthCare System Department of Psychiatry and Behavioral
Sciences. He is a board-certified Psychiatrist and Clinical Investigator with more than 25 years of medical and more than 20 years of research experience in
human behavioral and clinical psychopharmacology. He has successfully combined his research interest, teaching, clinical, and administrative responsibilities
while focusing on eliminating external and internal barriers to development of novel and innovative treatments with the overall goal of reducing health disparities,
improving access to care and increasing the generalizability of clinical trials results.
Oleg V Tcheremissine et al., J Clin Trials 2017, 7:5 (Suppl)
DOI: 10.4172/2167-0870-C1-019